Refine your search
Collections
Journals
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Raza, M.
- Thermoregulatory and In-vivo Anti-Inflammatory Effects of Vigabatrin in Rat and Mice
Abstract Views :190 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmacology, College of Pharmacy, King Saud University. P O Box 2457. Riyadh 11451, SA
1 Department of Pharmacology, College of Pharmacy, King Saud University. P O Box 2457. Riyadh 11451, SA
Source
Scientia Pharmaceutica, Vol 68, No 4 (2000), Pagination: 379-388Abstract
Effects of acute administration of vigabatrin (VGB) that has significant GABA-mimetic properties were studied for its antiinflammatory, antigranuloma effects in rats and thermoregulatory actions in mice. Treatment of rats with VGB (125, 250 and 500 mg/kg, i.p doses) caused a significant and persistent inhibition in the carrageenan induced paw edema. Inhibitory effect at high dose (500 mg/kg, which was about 10-fold of the maximal effective dose 50 mg/kg in humans) was 40-, 41- and 39% of the control at 2-, 3- and 4 hours after the treatment. In cotton-pellet-granuloma study, only the high dose was significantly (P<0.05) effective and inhibition in granuloma was 17 and 28% of the control at 250 and 500 mg/kg doses, respectively. In another model, leukocyte migration to the inflamed peritoneal cavity was used as a parameter in rats. In this model, VGB (500 mg/kg, i.p) induced a significant (P<0.05) reduction in leukocyte migration to the inflamed peritoneal cavity when administered 30 min before carrageenan This was comparable to indomethacin (10 mg/kg) that also caused a significant (P<0.05) reduction in leukocyte migration. The inhibition in the leukocyte migration was 66 and 61% with VGB and indomethacin, respectively. In thermoregulation studies, the rectal temperature of normothermic mice declined dose dependently. In another part of this study all the doses of VGB induced a significant reduction in body temperature at 45 min following drug administration in yeast-induced hyperpyrexic mice. The hypothermic response diminished after 90 min, 3 hours and 6 hours of treatment at 125, 250 and 500 mg/kg doses respectively and none of the dose showed any change in rectal temperature at 24-hour study point.
The results of the present study indicate that vigabatrin has the potential to induce anti-edema, antigranuloma and leukocyte anti-migratory effects in inflamed peritoneal cavity and reduce the rectal temperature in normothermic as well as hyperthermia-induced mice with acute regimen. These effects are thought to be the result of GABA accumulation, its interaction with PG biosynthesis and other neuromediators.
Keywords
Vigabatrin, inflammation, thermoregulation, granuloma, leukocyte migration
References
- Palfreyman MG, Schechter PJ, Buckett WR, Tell GP, Koch-Weser J. (1981), Biochem. Pharmacol. 30: 817-824.
- Löscher W. Valproic acid. In: Antiepileptic drugs. Handbook of experimental Pharmacology, Eds. Frey HH, Janz D. Vol. 74, Springer-Verlag, Berlin. (1985), pp. 507-842.
- Jung MJ, Lippert B, Metcalf BW, Bohlen P, Schechter PJ (1977), J. Neurochem. 29: 797-802.
- Jung MJ, Lippert B, Metcalf BW, Schechter PJ, Bohlen P, Sjoerdsma A. (1977), J. Neurochem.
- : 717-723.
- Ben-Menachem E, Persson LI, Schchter PJ, Haegle KD, Huebert N, Hardenberg J, Dahlgren L, Mumford JP. (1989), Brit. J. Clin. Pharmacol. 27 (suppl. 1): 79S-85S.
- Hammond EJ, Wilder BJ. (1985), Clin. Neuropharmacol. 8: 1-12
- Michelucci R., Tassinari C.A. (1989), Brit. J. Clin. Pharmacol. 27 (Suppl 1): 119S-124S.
- Myslobodsky M.S., Ackermann R.F. and Engel Jr. (1979), Pharmacol. Biochem. Behav. 11(3): 265-271. '
- Kalichman MW, McIntyre Burnham W, Livingstone KE. (1982), Neuropharmacol. 21: 127.
- Shin C, Rigsbee LC, McNamara IP. (1986), Brain. Res. 398: 370-374.
- Schechter PJ. Vigabatrin. In: New anticonvulsant drugs. Eds. Meldrum RS, Porter RJ. John Libby, London. (1986), pp. 265-275.
- Löscher W., Schmidt D. (1988), Epilepsy Res. 2: 145-181.
- RimmerE.M and Richens A.R. (1984), Lancet i: 189-190.
- Gram L., Klosterkov P., Dam M. (1985), Annals. Neurol. 17: 262-267
- Loiseau P., Hardenberg J.P, Pestre M., Guyot M , Schechter P J. and Tell G.P. (1986), Epilepsia 27 (2): 115-120.
- Remy C., Favel P., Tell G., Hardenberg J , Schechter P J. (1986), Boll Lega Ital Epil 54/55: 241-243. "
- Tartara A , Manni A., Galimberti C A., Hardenberg J., Orwin J and Perucca E (1986), Epilepsia 27: 717-723.
- Tassinari C.A , Michelucci R , Ambrosetto G and Salvi F (1987), Annals Neurol. 44: 907910.
- Reynolds E.H., Ring H.A., Farr I.N., Heller A.J., Elwes, R D C. (1991), Epilepsia 32: 530-538.
- McKee PJW, Blacklaw J, Friel E, Thompson GG, Gillham RA, Brodie MJ. (1993), Epilepsia 34(5): 937-943.
- Zarrindast MR, Dibayan M. (1989), Gen. Pharmacol. 20: 855-859
- Horton RW. GABA, epilepsy and anticonvulsant drugs. In: What is epilepsy. The Scientific and clinical basis of epilepsy. Edited by Trimble MR, Reynolds EH Churchill Livingstone, London. (1986), pp. 281-292. ”
- Krnjevie K. Significance of GABA in brain function. In: GABA mechanisms in epilepsy. Eds. Tunncliff G, Raess BU. Wiley-Liss New York. (1991), pp. 47-87.
- Ticku MK. Mechanism of GABA agonists and modulators of GABAergic transmission in anticonvulsant activity. In: GABA mechanisms in epilepsy. Edited by Tunnicliff G, Raess BU. Wiley Liss, New York. (1991), pp. 149-164.
- Emrich JHM, Wolf R. Valproate and mania. In: Fourth International Symposium on Sodium Valproate and Epilepsy, Editor, Chadwick D, Royal Society of Medicine Services, London. (1989), pp. 217-224.
- De-Feudis FV. (1982), Pharmacol. Res. Commun. 14: 383-389.
- De-Feudis FV. (1982), Trends Pharmacol. Sei. 3: 444-446.
- Buckett WR. (1980), Neuropharmacol. 19:715-722.
- Marsden CD. (1982), A Lancet Rev. 21-27.
- Haefly W. Benzodiazepines: Mechanism of action. In: Epileptic Drugs, 3rd Edn. Edited by Levy RH, Mattson R, Meldrum B, Penry JK Dreifuss FE. Raven Press, New York (1989), pp. 721-734.
- Mumford JP, Cannon DJ (1994), Epilepsia 35(5): S25-S28.
- Ferkany JW, Smith LA, Seifert WE, Caprioli RM, Enna SJ. (1978) Life Sei. 22: 2121-2128.
- BertilssonL, Suria A, Costa E. (1976), Nature (London) 260: 540-541.
- Okada Y, Tanguchi H, Schimada C. (1976), Science 194: 620-622.
- Krogsgaard-Larsen P. (1981), J. Med. Chem. 24: 1377-1387.
- De-Feudis FV, Orensanz-Munoz LM. Vertebrate GABA-receptors, Involvement in CNS functions and behavior. In: Neurotransmitters, Receptors and Drug Action (Edited by Sussman WB). Spectrum, New York. (1980) pp. 143-178.
- Winter CA, Risley EA, Nuss GW. (1962), Proc. Soc. Exp. Biol. Med. 111:544-547.
- Raza M, Dhariwal MAH, Ageel AM, Qureshi S. (1996), Gen. Pharmacol. 27(8): 1395-1400.
- Goldstein S, Shemano I, Demeo R, Beiler JM. (1967), Arch. Int Pharmacodyn. Thrap 167: 79-53.
- Baird AW, Cuthbert AW, Mac Vinish LJ. (1987), Brit. J. Pharmacol. 91(4): 857-869.
- Loux JJ, Depalma PD, Yankell SL. (1972), Toxicol. Appl. Pharmacol. 22: 672-675.
- Bonta IL. Handbook of experimental Pharmacology, Vol. 50/1, Eds Vane JR, Ferreira SH. Springer Verlag, New York. (1978), pp. 523-567,
- Van Arman CG, Begany AJ, Miller LM, PlessHH. (1965), J. Pharmacol. Exp. Med. 150(2): 328-334.
- Turner RA. Screening Methods in Pharmacology. Academic Press, New York. (1965), pp. 1,
- and 158
- DiRosaM, Giround JP, Willoughby DA. (1971), J. Pathol. 104: 15-29.
- El-Mahdy SA, Alhaider AA, Mahgoub AA. (1990), J Pharmac Pharmacol. 42(7): 522-524
- Bhattacharya SK, SarkarMK (1986), J. Pharmac. Pharmacol. 38:144-146.
- Bhattacharya SK, Das N (1984), J. Pharmac. Pharmacol 36: 368-369
- Bhattacharya SK, Das N. (1985) Agents Actions. 17(2): 150-152.
- Bhattacharya SK, Das N, SarkarMK. (1987), Res Exp. Med -Berlin 187(4): 303-313.
- Lippert B, Metcalf BW, Jung MJ, Casara P (1977), Eur. J Biochem 74: 441-445.
- Neal MJ, Shah MA. (1990) Brit. J Pharmacol. 100: 324-328
- Iadarola MJ, Gale K. (1981), Science 218: 1237-1240.
- Neal MJ, Cunningham JR, Shah MA. Neuronal and glial release of GABA from rat retina. In: Neurobiology of the inner retina. NATO ASI Series, Series H: Cell Biology, 31, Ed. Weiler R. and Osborne NN. (1989), pp. 77-89.
- Iversen LL. Psychopharmacology: A generation of progress. Eds. Lipton MA, DiMascio A, Killam KF. Raven Press, New York, (1978), pp. 25-38.
- Pradhan NS, Bose S. In: Psychopharmacology: A generation of progress. Eds. Lipton MA, DiMascio A, Killam KF. Raven Press, New York, (1978), pp. 271-281.
- Rolf LH, Voges B. (1993), Epilepsy Res. 16(3): 235-239.
- Castro-Lopes JM, Tavares I, Tolle TR, Coimbra A. (1994), Pain 56(2): 193-201.
- Insel PA. Analgesics, antipyretic and antiinflammatory drugs employed in the treatment of rheumatoid arthritis and gout. In: The Pharmacological Basis of Therapeutics. Eds. Gillman AG, Rail TW, Nies AS, Taylor P. Pergamon Press, New York, 8th Edition, (1991), pp. 638681. ' '
- Seng GF, Benensohen J, Bayer BM. (1990), Eur. J. Pharmacol. 178: 267-273.
- De-Souza GE, Ferreira SH. (1985), Agents Actions 17(1): 97-103.
- Souza CA, Cunha FQ, Ferreira SH. (1994), Brazil J. Med. Biol. Res. 27(3): 663-670.
- Hidaka T, Hosoe K, Ariki Y, Takeo K, Yamashita T, Katsumi I, Kando H, Yamashita K, Watanabe K. (1984), Japan. J. Pharmacol. 36: 77-85.
- Hidaka T, Takeo K, Hoseo K, Katsumi I, Yamashita T, Watanabe K (1985), Japan. J Pharmacol. 38(3): 267-272. '
- Higgs GA, Eakins KE, Mugridge KG, Moncada S, Vane JR. (1980), Eur. J. Pharmacol. 66(1): 81-86.
- SamuelssonB. (1983), Science 220 (4597): 568-575.
- Vazquez B, Avila G, Segura D, Escalente B. (1996), J. Ethnopharmacol. 55(1): 69-75.
- Yamashita T, Ishibashi Y, Nagaoka I, Kasuya K, Masuda K, Warabi H, Shiokawa Y (1982), Inflammation 6(1): 87-101.
- Blackham A, Norris AA, Woods FA. (1985), J Pharmac. Pharmacol. 37(11): 787-793.
- Souza MH, Milo-Filho AA, Rocha MF, Lyerly DM, Cunha FQ, Lima AA, Ribeiro RA (1997), Immunology 91(2): 281-288.
- Rocha MF, Maia ME, Bezerra LR, Lyerly DM, Guerrant RL, Ribeiro RA, Lima AA. (1997), Infect. Immun. 65(7): 2740-2746.
- Römstedt K, Huzoor-Akbar. (1985), Thromb. Res 38: 361-374.
- Bartholini G, Stadler H. (1977), Neuropharmacol. 16: 343-347.
- Chapman A, Keane PE, Meldrum BS, Simiand J, Vernieres JC. (1982), Prog. Neurobiol. 19: 315-359.
- Zarrindast MR, Oveissi Y. (1988), Gen. Pharmacol. 19: 223-226.
- Ghosh S, PoddarMK. (1995), Biochem. Behav. 52(1): 73-76.
- Ghosh S, Poddar MK. (1993), Neurochem. Res. 18(12): 1287-1292.
- Sancibrian M,Serrano JS, Minano FJ. (1991), Gen. Pharmacol. 22: 259-262.
- Morishima Y, Shibano T. (1995), Pharmacol Biochem. Behav. 52: 755-758.
- Serrano JS, Minano FJ, Sancibrian M. (1986), Gen. Pharmacol. 17: 327-332.
- Minano FJ, Sancibrian M, Serrano JS. (1987), Methods Find. Exp. Clin Pharmacol. 9: 225231,
- De-Bernardis E, Caruso A, Cutuli VM, Lucenti A, Villari L, Amico-Roxas M. (1993), J Phys 87: 389-392.
- Effect of Prolonged Vigabatrin Treatment on Hematological and Biochemical Parameters in Plasma, Liver and Kidney of Swiss Albino Mice
Abstract Views :586 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmacology, College of Pharmacy, King Saud University, P O Box 2457, Riyadh 11451, SA
1 Department of Pharmacology, College of Pharmacy, King Saud University, P O Box 2457, Riyadh 11451, SA
Source
Scientia Pharmaceutica, Vol 70, No 2 (2002), Pagination: 135-145Abstract
We have evaluated vigabatrin (γ-vinyl γ-aminobutyric acid), an irreversible inhibitor of γ-aminobutyric acid (GABA)-transaminase responsible for GABA degradation, for its effects on food consumption, body weight changes, fluid intake, changes in hematological and biochemical parameters in plasma liver and kidney of Swiss albino mice. Mice received vigabatrin 0.26% wlv chronically in drinking water for 7, 14 and 21 days. Changes in all the parameters were recorded after 7, 14 and 21 days respectively in different groups. Food consumption was comparable to the control group with minor fluctuations. The body weight declined significantly but only after 3-week treatment with no appreciable change in organ indices or relative organ indices. There were essentially no adverse effects on hematological parameters (RBC, WBC, HGB, neutrophils, eosinophils, monocytes, lymphocytes and basophils) with this treatment. However, there was a decrease in monocyte counts during the first week and an increase in the neutrophil counts during the third week of vigabatrin treatment. In one part plasma biochemical parameters like AST, ALT, CK-MB, creatinine, glucose and urea were also assessed with the same dose regimen. It was observed that only CK-MB and GPT activity levels were altered slightly significantly and are thought to be a result of cross enzyme inhibitions. In this experiment it was observed that lipid peroxide levels measured, as malondialdehyde did not change appreciably in both liver and kidney tissues. However, the levels of glutathione (non-protein sulfhydryl; GSH) declined significantly in comparison to control in liver and kidney. A comparison of level of GSH in liver and kidney shows that this depletion was at early time points in the former. The depletion of GSH suggests the possible involvement of GSH in detoxification process and corroborates its role in protection.Keywords
Vigabatrin, Hematology, Plasma, Liver, Kidney, BiochemistryReferences
- Bartoli A., Gatti G.,. Cipolla G., Barzaghi N., Veliz G., Fattore C., Mumford J., Perucca E. (1997), Epilepsia; 38:702-707.
- Ferkany J. W., Smith L. A., Scifert W.E., Caprioli R.M., Enna S.J. (1978), Life Sci. 22: 2121-2128.
- Bertilsson L., Suria A,, Costa E. (1976), Nature (London). 260: 540-541.
- Okada Y., Tanguchi H., Schimada C. (1976), Science. 194: 620-622.
- Raza M., Al-Shabanah O.A., Al-Harbi M.M., El-Hadiyah T.M.H., Qureshi S. (2000), Saudi Pharm. J. 8(4): 164-174.
- Raza M., Al-Shabanah O.A., Al-Harbi M.M., El-Hadiyah T.M.H., Qureshi S. (2000), Sci. Pharm. 68: 379-388.
- Raza M., Al-Shabanah O. A., El-Hadiyah T.M., Al-Bekairi A.M., Qureshi S. (2001), Sci. Pharm. 69: 203-210.
- Mazurkiewicz M., Sirvio J., Riekkinen P.Sr. (1992), Epilepsy Res. 12: 231-237.
- Ohkawa H., Ohishi N., Yagi K. (1979), Anal. Biochem. 95: 351-358.
- Sedlak J., Lindsay R.H., (1968), Anal. Biochem.25: 192-205.
- Huot S., Palfreyman M.G. (1982), Pharmacol. Biochem. Behav. 17: 99-106.
- Singewald N., Pfitscher A., Philippu A. (1992), Naunyn Schmiedebergs Arch. Pharmacol. 345: 181-186.
- Gibson J.P., Yarrigton J.T., Loudy D.E., Gerbig C.G., Hurst G.H., Newberne J.W. (1990), Toxicol. Pathol. 18: 225-238.
- Frisk-Holmberg M., Kerth P., Meyer P. (1989), Br. J. Clin. Pharmacol. 27(suppl 1): 23s-25s.
- Jung M.J., Lippert B., Metcalf B.W., Bohlen P., Schechter P.J. (1977), J. Neurochem. 29: 797-802.
- Ben-Menachem E., Persson L.I., Schechter P.J., Haegele K.D., Huebert N., Hardenberg J., Dahlgren L., Mumford J.P. (1989), Br. J. Clin. Pharmacol. 27 (suppl. 1): 79s-85s.
- Richens A. (1991), J. Child. Neurol. (Suppl. 2): S7-S10.
- Cocito L., Maffini M., Loeb C. (1993), Seizure. 2: 301-307.
- Vogt H., Kramer G. (1995), Schweiz. Med. Wochenschr. 125: 125-132.
- Herranz J.L., Arteaga R., Farr I.N., Valdizan E., Beaumont D., Armijo J.A. (1991), J. Child. Neurol. (Suppl), 2: S45-S51.
- Kaplan A,, Szabo L.L. (1983), Enzymes In: Clinical Chemistry: Interpretations and Techniques. Lea and Febiger, Philadelphia, 2nd edition, pp. 173-218.
- Foletti G.B., Delisle M.C., Bachmann C. (1995), Epilepsia. 38: 804-809.
- Enna S.J. (1981). Neuropharmachemical and clinical aspects of γ-aminobutyric acid (GABA). In: Neuropharmacolgy of central and behavioral disorders. Ed. Palmer G. Academic Press, New York, Pp. 507-537.
- Gilon P., Bertrand G., Loubatieres-Mariani M.M., Remacle C., Hanquin J.C. (1991), Endocrinology. 129: 2521-2529.
- Kosower N.S., Kosower E.M. (1983), Glutathione and cell membrane thiol status. In: Functions of glutathione. Eds. Larsson A., Orrenius S., Holmgren A., Mannervick B. Raven Press, New York Pp. 307-315.
- Bellomo G., Orrenius S. (1985), Hepatology, 5: 876-882.
- Rogers C., Brown A,, Szabo S. (1988), Dig. Dis. Sci. 33: 324-329.
- Szabo S., Trier J.S., Frankel P.W. (1981), Science. 214: 200-202.
- Raza M., Al-Bekairi A.M., Ageel A.M., Qureshi S. (1997), Pharmacol. Res. 35: 153-157.